Table 1 Baseline characteristics of the patients who underwent ERCP after Billroth II surgery
Variables | Total (N = 79) | Cap-assisted gastroscope (N = 45, 57%) | Duodenoscope (N = 34, 43%) | P value |
|---|---|---|---|---|
Age, yrs | 76 (68–83) | 76 (69–84) | 76 (68-81.5) | 0.696 |
Male, yrs | 75 (66–82) | 75 (66–84) | 74 (67–80) | 0.523 |
Female, yrs | 81 (74–85) | 81 (74–84) | 78 (76–86) | 0.791 |
Sex | 0.686 | |||
Male | 61 (77.2) | 34 (75.5) | 27 (79.4) | |
Female | 18 (22.8) | 11 (25.5) | 7 (21.6) | |
BMI, kg/m2 | 21.4 (19.1–22.9) | 21.1 (18.6–22.9) | 21.5 (20.7–22.9) | 0.158 |
Indications for ERCP | 0.700 | |||
Choledocholithiasis | 69 (87.3) | 40 (88.9) | 29 (85.3) | |
Malignant obstruction | 7 (8.9) | 3 (6.7) | 4 (11.8) | |
Clinical cholangitis | 3 (3.8) | 2 (4.4) | 1 (2.9) | |
Laboratory tests before ERCP | ||||
WBC, /µL | 9700 (7050–13100) | 9200 (6600–11500) | 11,500 (7750–14725) | 0.055 |
AST, U/L | 159 (66.25-288.75) | 145 (51–322) | 163 (72–240) | 0.784 |
ALT, U/L | 133 (67.5–221) | 133 (74–221) | 130 (65–221) | 0.768 |
Total bilirubin, mg/dL | 2.7 (1.35–4.74) | 2.5 (0.81–4.6) | 3.23 (1.8–5.17) | 0.087 |
ALP, U/L | 267 (173–407) | 266 (165-386.75) | 267 (181–426) | 0.257 |
GGT, U/L | 291 (179–457) | 273 (168.75–429.5) | 317 (182–426) | 0.973 |
Amylase, U/L | 50.5 (36-78.75) | 57 (36-102.5) | 47 (36.5–67) | 0.148 |
Lipase, U/L | 33 (19–72) | 38 (21.5-105.5) | 24 (17–44) | 0.106 |